在晚期NSCLC患者的化学免疫疗法/免疫疗法下生存的治疗前预后因素
Julija Judickiene1, Martin Metzenmacher2, Gregor Zaun3
1Department of Medical Oncology, West German Cancer Centre, Essen, Germany; Department of Thoracic Oncology, Ruhrlandklinik, Essen, Germany; Department of Pulmonology, Interventional Bronchology, West German Cancer Center, Essen, Germany.
European journal of cancer (Oxford, England : 1990)
|March 4, 2026
概括
五个治疗前的因素预测了接受免疫治疗的高级非小细胞肺癌 (NSCLC) 患者的结果. 识别这些因素可以帮助估计NSCLC的早期治疗失败.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肺癌研究研究 肺癌研究
背景情况:
- 检查点抑制剂治疗 (PD-1/PD-L1抗体) 对晚期非小细胞肺癌 (NSCLC) 有好处.
- PD-L1表达是治疗反应的弱预测指标.
- 预后因素,如ECOG状态,LDH,CRP和突变对NSCLC免疫治疗结果的影响还不清楚.
研究的目的:
- 确定预治疗因素,预测晚期NSCLC患者接受化疗免疫疗法或单疗法的结果.
- 分析这些因素对整体生存 (OS) 和无进展生存 (PFS) 的影响.
主要方法:
- 两组患者的回顾性分析:"超级响应者" (OS>24个月) 和初级进展者 (PFS <10个月).
- 分析了包括ECOG状态,PD-L1瘤比例得分 (TPS),血清LDH,血清CRP和KEAP-1突变在内的因素.
- 采用了单变量和多变量统计方法.
主要成果:
- 在单变量分析中,有五个因素对OS产生影响:ECOG状态,PD-L1 TPS,LDH,CRP和KEAP-1突变.
- 多变量分析证实了这五个因素的独立影响.
- 在无进展生存期 (PFS) 中观察到类似的影响.
结论:
- 初始ECOG为零,LDH和CRP不升高,PD-L1阳性,KEAP1突变不存在是晚期NSCLC患者的独立预后参数.
- 这些发现有助于估计侵袭性肺癌的早期治疗失败.
- 计划在一个更大,未经选择的群体中进行潜在的确认.
相关概念视频
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:21Cancer Survival Analysis
806
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
806
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:30Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K